ARDS
Income statement / Annual
Last year (2022), Aridis Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Aridis Pharmaceuticals, Inc.'s net income was -$30.75 M.
See Aridis Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$1.00 M
|
$1.02 M
|
$2.76 M
|
$860,000.00
|
$2.27 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.93 M |
| Gross Profit |
$0.00 |
$0.00 |
$1.00 M |
$1.02 M |
$2.76 M |
$860,000.00 |
$342,000.00 |
| Gross Profit Ratio |
0 |
0 |
1 |
1 |
1 |
1 |
0.15 |
| Research and Development
Expenses |
$25.92 M
|
$37.94 M
|
$16.96 M
|
$24.08 M
|
$23.00 M
|
$17.44 M
|
$6.26 M
|
| General & Administrative
Expenses |
$7.16 M
|
$7.31 M
|
$6.45 M
|
$6.03 M
|
$3.87 M
|
$3.16 M
|
$1.97 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$7.16 M
|
$7.31 M
|
$6.45 M
|
$6.03 M
|
$3.87 M
|
$3.16 M
|
$1.97 M
|
| Other Expenses |
-$3.09 M |
-$1.54 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$29.99 M |
$43.71 M |
$23.40 M |
$30.11 M |
$26.87 M |
$20.60 M |
$8.23 M |
| Cost And Expenses |
$29.99 M |
$43.71 M |
$23.40 M |
$30.11 M |
$26.87 M |
$20.60 M |
$10.15 M |
| Interest Income |
$0.00 |
$0.00 |
$77,000.00 |
$357,000.00 |
$0.00 |
$234,000.00 |
$0.00 |
| Interest Expense |
$378,000.00 |
-$245,000.00 |
$0.00 |
$0.00 |
$420,000.00 |
$0.00 |
$366,000.00 |
| Depreciation &
Amortization |
$487,000.00
|
-$722,000.00
|
$337,000.00
|
$338,000.00
|
$283,000.00
|
$62,000.00
|
$23,000.00
|
| EBITDA |
-$29.51 M
|
-$44.43 M
|
-$22.06 M
|
-$28.75 M
|
-$23.83 M
|
-$19.68 M
|
-$7.86 M
|
| EBITDA Ratio |
0 |
0 |
-22.4 |
-28.46 |
-9.34 |
-16.89 |
-3.39 |
| Operating Income Ratio
|
0
|
0
|
-22.4
|
-28.46
|
-8.75
|
-22.95
|
-3.47
|
| Total Other
Income/Expenses Net |
-$378,000.00
|
$1.52 M
|
$68,000.00
|
-$594,000.00
|
$2.01 M
|
-$4.92 M
|
-$538,000.00
|
| Income Before Tax |
-$30.37 M |
-$43.19 M |
-$22.33 M |
-$29.68 M |
-$22.11 M |
-$24.66 M |
-$8.42 M |
| Income Before Tax Ratio
|
0
|
0
|
-22.33
|
-29.04
|
-8.02
|
-28.67
|
-3.71
|
| Income Tax Expense |
$378,000.00 |
-$912,000.00 |
-$414,000.00 |
-$695,000.00 |
$2.43 M |
$4.92 M |
$538,000.00 |
| Net Income |
-$30.75 M |
-$42.28 M |
-$21.92 M |
-$28.99 M |
-$22.11 M |
-$24.66 M |
-$8.42 M |
| Net Income Ratio |
0 |
0 |
-21.92 |
-28.36 |
-8.02 |
-28.67 |
-3.71 |
| EPS |
-1.64 |
-3.44 |
-2.39 |
-3.43 |
-7.02 |
-3.12 |
-1.07 |
| EPS Diluted |
-1.64 |
-3.44 |
-2.39 |
-3.43 |
-7.02 |
-3.12 |
-1.07 |
| Weighted Average Shares
Out |
$18.78 M
|
$12.29 M
|
$9.17 M
|
$8.46 M
|
$3.15 M
|
$7.89 M
|
$7.89 M
|
| Weighted Average Shares
Out Diluted |
$18.78 M
|
$12.29 M
|
$9.17 M
|
$8.46 M
|
$3.15 M
|
$7.89 M
|
$7.89 M
|
| Link |
|
|
|
|
|
|
|
